Protein-prime/modified vaccinia virus Ankara vector-boost vaccination overcomes tolerance in high-antigenemic HBV-transgenic mice

Vaccine

Volumn 34, Issue 7, 2016, Pages 923-932

  Backes, Simone ^a   Jäger, Clemens ^a   Dembek, Claudia J ^a,b   Kosinska, Anna D ^a   Bauer, Tanja ^a,b   Stephan, Ann Sophie ^a   Dišlers, Andris ^c   Mutwiri, George ^d,e   Busch, Dirk H ^b,f,g   Babiuk, Lorne A ^h   Gasteiger, Georg ^a,g   Protzer, Ulrike ^a,b,g  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b German Center for Infection Research   (Germany)

^c UNIVERSITY OF LATVIA   (Latvia)

^d UNIVERSITY OF SASKATCHEWAN   (Canada)

^e UNIVERSITY OF SASKATCHEWAN   (Canada)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g INSTITUTE OF EPIDEMIOLOGY   (Germany)

^h UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Hepatitis B virus; Heterologous prime boost strategy; Recombinant MVA; Therapeutic vaccination; Tolerance

Indexed keywords

HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; NEUTRALIZING ANTIBODY; PROTEIN MODIFIED VACCINIA VIRUS ANKARA VECTOR BOOST VACCINE; UNCLASSIFIED DRUG; HEPATITIS B ANTIBODY; HEPATITIS B(E) ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC HEPATITIS B; CONTROLLED STUDY; HEPATITIS B VIRUS; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; SEROCONVERSION; VACCINATION; VACCINIA VIRUS; ANIMAL; BLOOD; C57BL MOUSE; HEPATITIS B; IMMUNOLOGY; SECONDARY IMMUNIZATION; SERODIAGNOSIS; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, NEUTRALIZING; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; IMMUNE TOLERANCE; IMMUNIZATION, SECONDARY; MICE, INBRED C57BL; MICE, TRANSGENIC; NEUTRALIZATION TESTS; VACCINIA VIRUS;

EID: 84957851250     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.12.060     Document Type: Article

References (39)

1. Rehermann B., Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005, 5(3):215-229.
2. Ilan Y., Nagler A., Adler R., Tur-Kaspa R., Slavin S., Shouval D. Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor. Gastroenterology 1993, 104(6):1818-1821.
3. Kutscher S., Bauer T., Dembek C., Sprinzl M., Protzer U. Design of therapeutic vaccines: hepatitis B as an example. Microb Biotechnol 2012, 5(Mar (2)):270-282.
4. Michel M.L., Deng Q., Mancini-Bourgine M. Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. J Hepatol 2011, 54(6):1286-1296.
5. Guidotti L.G., Matzke B., Schaller H., Chisari F.V. High-level hepatitis B virus replication in transgenic mice. J Virol 1995, 69(10):6158-6169.
6. Shimizu Y., Guidotti L.G., Fowler P., Chisari F.V. Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice. J Immunol 1998, 161(Nov (9)):4520-4529.
7. Buchmann P., Dembek C., Kuklick L., Jager C., Tedjokusumo R., von Freyend M.J., et al. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice. Vaccine 2013, 31(Feb (8)):1197-1203.
8. Farag M.M., Tedjokusumo R., Flechtenmacher C., Asen T., Stremmel W., Muller M., et al. Immune tolerance against HBV can be overcome in HBV transgenic mice by immunization with dendritic cells pulsed by HBVsvp. Vaccine 2012, 30(Sep (42)):6034-6039.
9. Stross L., Gunther J., Gasteiger G., Asen T., Graf S., Aichler M., et al. Foxp3+ regulatory T cells protect the liver from immune damage and compromise virus control during acute experimental hepatitis B virus infection in mice. Hepatology 2012, 56(Sep (3)):873-883.
10. Untergasser A., Zedler U., Langenkamp A., Hosel M., Quasdorff M., Esser K., et al. Dendritic cells take up viral antigens but do not support the early steps of hepatitis B virus infection. Hepatology 2006, 43(3):539-547.
11. Lucifora J., Arzberger S., Durantel D., Belloni L., Strubin M., Levrero M., et al. Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J Hepatol 2011, 55(Nov (5)):996-1003.
12. Mutwiri G., Benjamin P., Soita H., Babiuk L.A. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen. Vaccine 2008, 26(May (22)):2680-2688.
13. Awate S., Wilson H.L., Lai K., Babiuk L.A., Mutwiri G. Activation of adjuvant core response genes by the novel adjuvant PCEP. Mol Immunol 2012, 51(Jul (3-4)):292-303.
14. Wyatt L.S., Shors S.T., Murphy B.R., Moss B. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine 1996, 14(Oct (15)):1451-1458.
15. Schirmbeck R., Dikopoulos N., Kwissa M., Leithauser F., Lamberth K., Buus S., et al. Breaking tolerance in hepatitis B surface antigen (HBsAg) transgenic mice by vaccination with cross-reactive, natural HBsAg variants. Eur J Immunol 2003, 33(12):3342-3352.
16. Dahmen A., Herzog-Hauff S., Bocher W.O., Galle P.R., Lohr H.F. Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B. J Med Virol 2002, 66(4):452-460.
17. Horiike N., Fazle Akbar S.M., Michitaka K., Joukou K., Yamamoto K., Kojima N., et al. In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B. J Clin Virol 2005, 32(2):156-161.
18. Vandepapeliere P., Lau G.K., Leroux-Roels G., Horsmans Y., Gane E., Tawandee T., et al. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 2007, 25(Dec (51)):8585-8597.
19. Cavenaugh J.S., Awi D., Mendy M., Hill A.V., Whittle H., McConkey S.J. Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection. PLoS ONE 2011, 6(2):e14626.
20. Yang F.Q., Yu Y.Y., Wang G.Q., Chen J., Li J.H., Li Y.Q., et al. A pilot randomized controlled trial of dual-plasmid HBV DNA vaccine mediated by in vivo electroporation in chronic hepatitis B patients under lamivudine chemotherapy. J Viral Hepat 2012, 19(8):581-593.
21. Sette A.D., Oseroff C., Sidney J., Alexander J., Chesnut R.W., Kakimi K., et al. Overcoming T cell tolerance to the hepatitis B virus surface antigen in hepatitis B virus-transgenic mice. J Immunol 2001, 166(Jan (2)):1389-1397.
22. Bertoletti A., Gehring A. Therapeutic vaccination and novel strategies to treat chronic HBV infection. Expert Rev Gastroenterol Hepatol 2009, 3(Oct (5)):561-569.
23. Op den Brouw M.L., Binda R.S., van Roosmalen M.H., Protzer U., Janssen H.L., van der Molen R.G., et al. Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus. Immunology 2009, 126(2):280-289.
24. Milich D.R., McLachlan A. The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen. Science 1986, 234(Dec (4782)):1398-1401.
25. Yang P.L., Althage A., Chung J., Maier H., Wieland S., Isogawa M., et al. Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci USA 2010, 107(Jan (2)):798-802.
26. Asabe S., Wieland S.F., Chattopadhyay P.K., Roederer M., Engle R.E., Purcell R.H., et al. The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol 2009, 83(Oct (19)):9652-9662.
27. Ferrari C., Penna A., Bertoletti A., Valli A., Antoni A.D., Giuberti T., et al. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 1990, 145(Nov (10)):3442-3449.
28. Jung M.C., Diepolder H.M., Spengler U., Wierenga E.A., Zachoval R., Hoffmann R.M., et al. Activation of a heterogeneous hepatitis B (HB) core and e antigen-specific CD4+ T-cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection. J Virol 1995, 69(6):3358-3368.
29. Wherry E.J. T cell exhaustion. Nat Immunol 2011, 12(6):492-499.
30. Wherry E.J., Blattman J.N., Murali-Krishna K., van der Most R., Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 2003, 77(Apr (8)):4911-4927.
31. Pantaleo G., Harari A. Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases. Nat Rev Immunol 2006, 6(5):417-423.
32. Seder R.A., Darrah P.A., Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008, 8(4):247-258.
33. Guidotti L.G., Ando K., Hobbs M.V., Ishikawa T., Runkel L., Schreiber R.D., et al. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci USA 1994, 91(Apr (9)):3764-3768.
34. Guidotti L.G., Ishikawa T., Hobbs M.V., Matzke B., Schreiber R., Chisari F.V. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996, 4(1):25-36.
35. Lucifora J., Xia Y., Reisinger F., Zhang K., Stadler D., Cheng X., et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 2014, 343(Mar (6176)):1221-1228.
36. Barber D.L., Wherry E.J., Masopust D., Zhu B., Allison J.P., Sharpe A.H., et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439(Feb (7077)):682-687.
37. Maier H., Isogawa M., Freeman G.J., Chisari F.V. PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver. J Immunol 2007, 178(Mar (5)):2714-2720.
38. Velu V., Titanji K., Zhu B., Husain S., Pladevega A., Lai L., et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 2009, 458(Mar (7235)):206-210.
39. Liu J., Zhang E., Ma Z., Wu W., Kosinska A., Zhang X., et al. Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog 2014, 10(1):e1003856.